BioSpace News Archive

Novocardia today announced the appointment of several new executive team members charged with accelerating the company’s mission to improve access to high-quality, high-value cardiovascular disease care.

Incyte (Nasdaq: INCY) today announced that Health Canada has granted a Notice of Compliance with conditions for Minjuvi® (tafasitamab)

EOM Pharmaceuticals, Inc. announced the first patients have been dosed in R1: RESCUE, a proof-of-concept Phase 1/2a open-label multicenter clinical study in Brazil to evaluate safety, tolerability, and preliminary efficacy of EOM613 in hospitalized COVID-19 infected patients with severe symptoms.

DiCE Molecules today announced the completion of its $60 million Series C-1 financing.

Abveris, Inc. (“Abveris”) and Abilita Bio, Inc. announce a joint research collaboration that will leverage the synergies between their platforms to enable the discovery of novel antibodies targeting key GPCRs within the tumor immune microenvironment.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has entered into a reference lab agreement to provide cPass neutralizing antibody blood testing services to Meadowlands Diagnostics, a CLIA-certified New Jersey-based provider of laboratory testing services.

MicroQuin Ltd, today announced it has signed a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the potential of MicroQuin therapeutics (MQPs) and move them towards clinical trials as treatments for of a range of viruses including influenza, SARS-CoV-2, respiratory syncytial virus (RSV) and adenovirus.

Mental health issues, especially those related to depressive disorders, have increased dramatically during the COVID-19 pandemic and with hopes for shining light on a new approach to combating these issues, renowned Microbiome Scientist, Mahmoud Ghannoum, PhD., FAAM, FIDSA shares findings for rebalancing the microbiome to treat depression in a groundbreaking peer-reviewed article

The National Kidney Foundation and the American Society of Nephrology congratulate the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases for submitting its final report for publication.

Atavistik Bio (“Atavistik”, “Company”), a pre-clinical biotechnology company pioneering the identification of metabolite-protein interactions that have the potential to lead to the discovery and development of first-in-class drug candidates powered by distinct allosteric control mechanisms, announced today that the Company had completed a $60 million Series A financing round.